Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant RecipientsVikas S. Sridhar, Sunita Singh, Massimo Nardone et al.|Clinical Journal of the American Society of Nephrology|2025Cited by 6
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled TrialVikas S. Sridhar, David Z.I. Cherney, Luxcia Kugathasan et al.|Hypertension|2025Cited by 1
Cardio-Kidney Effects of Dapagliflozin in Patients at Elevated Cardiovascular Risk with or Without Type 2 DiabetesVikas S. Sridhar, David Z.I. Cherney, Luxcia Kugathasan et al.|Journal of the American Society of Nephrology|2025Cited by 0